https://investors.karyopharm.com/ https://investors.karyopharm.com/2026-06-02-Karyopharms-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-Selected-for-Late-Breaking-Oral-Presentation-at-EHA-2026 Tue, 02 Jun 2026 10:02:00 -0400 https://investors.karyopharm.com/2026-06-02-Karyopharms-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-Selected-for-Late-Breaking-Oral-Presentation-at-EHA-2026 https://investors.karyopharm.com/2026-06-02-Karyopharm-to-Present-Results-from-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-in-Late-Breaking-Oral-Presentation-at-ASCO-2026-with-Simultaneous-Publication-in-the-Journal-of-Clinical-Oncology Tue, 02 Jun 2026 08:59:00 -0400 https://investors.karyopharm.com/2026-06-02-Karyopharm-to-Present-Results-from-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-in-Late-Breaking-Oral-Presentation-at-ASCO-2026-with-Simultaneous-Publication-in-the-Journal-of-Clinical-Oncology https://investors.karyopharm.com/2026-06-01-Karyopharm-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4 Mon, 01 Jun 2026 16:05:00 -0400 https://investors.karyopharm.com/2026-06-01-Karyopharm-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4 https://investors.karyopharm.com/2026-06-01-Karyopharm-to-Host-Investor-Conference-Call-Featuring-Expert-Perspectives-on-the-Phase-3-SENTRY-Trial-in-Myelofibrosis-Following-2026-ASCO-Presentation Mon, 01 Jun 2026 07:30:00 -0400 https://investors.karyopharm.com/2026-06-01-Karyopharm-to-Host-Investor-Conference-Call-Featuring-Expert-Perspectives-on-the-Phase-3-SENTRY-Trial-in-Myelofibrosis-Following-2026-ASCO-Presentation https://investors.karyopharm.com/2026-05-28-Karyopharm-to-Participate-at-the-2026-Jefferies-Global-Healthcare-Conference Thu, 28 May 2026 07:30:00 -0400 https://investors.karyopharm.com/2026-05-28-Karyopharm-to-Participate-at-the-2026-Jefferies-Global-Healthcare-Conference